2-Aminoquinoline compounds
View Patent ↗The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
1. A compound of structural formula (I):
wherein:
R 1 and R 2 are independently selected from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) C 2-6 alkenyl,
(4) C 2-6 alkynyl,
(5) cycloalkyl-C 0-6 alkyl,
(6) heterocycloalkyl-C 0-10 alkyl,
(7) aryl-C 0-10 alkyl, and
(8) heteroaryl-C 0-10 alkyl;
wherein alkyl, alkenyl, and alkynyl, moieties above are optionally substituted with one to four substituents independently selected from R a ; and wherein cycloalkyl, heterocycloalkyl aryl and heteroaryl moieties above are optionally substituted with one to four substituents independently selected from R b ; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
or, R 1 and R 2 together with the nitrogen atom to which they are attached, form a 4- to 11-membered bridged or unbridged or spirocyclic heterocyclic ring, optionally containing one or two additional heteroatoms selected from N, S, and O, optionally having one or more degrees of unsaturation, optionally fused to a 6-membered heteroaromatic or aromatic ring, either unsubstituted or substituted with one to four substituents independently selected from R b ; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
R 3 and R 4 are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C 1-8 alkyl,
(4) perfluoro C 1-6 alkyl,
(5) C 2-6 alkenyl,
(6) C 2-6 alkynyl,
(7) cycloalkyl,
(8) cycloalkyl-C 1-6 alkyl,
(9) cycloheteroalkyl,
(10) cycloheteroalkyl-C 1-6 alkyl,
(11) aryl,
(12) aryl-C 1-6 alkyl,
(13) heteroaryl,
(14) heteroaryl-C 1-6 alkyl,
(15) —OR 7 ,
(16) —NR 7 R 7 ,
(17) —CO 2 R 7 ,
(18) cyano, and
(19) —C(O)NR 7 R 7 ;
wherein alkyl, alkenyl and alkynyl, moieties above are optionally substituted with one to four substituents independently selected from R a ; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to four substituents independently selected from R b ; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
R 5 is
hydrogen
(6);
R 6 is selected from the group consisting of:
(1) —(CH 2 ) n -heteroaryl-R 7 ,
(2) —(CH 2 ) n NR 7 C(O)R 7 , and
(3) —(CH 2 ) n N(R 7 ) 2 , and
wherein one or two of the hydrogen atoms in (CH 2 ) n may be substituted with R a ;
R 7 is independently selected at each occurrence from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,
(6) heterocycloalkyl,
(7) aryl C 1-3 alkyl,
(8) heteroaryl C 1-3 alkyl,
(9) cycloalkyl C 1-3 alkyl,
(10) heterocycloalkyl C 1-3 alkyl,
(11) aryl C 2-3 alkenyl,
(12) heteroaryl C 2-3 alkenyl,
(13) cycloalkyl C 2-3 alkenyl, and
(14) heterocycloalkyl C 2-3 alkenyl,
wherein the alkyl and alkenyl moieties are optionally substituted with one to four substituents selected from R a ; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to four substituents selected from R b ; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
each R a is independently selected from:
(1) —OR d ,
(2) —NR d S(O) m R d ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m R d ,
(6) —SR d ,
(7) —S(O) 2 OR d ,
(8) —S(O) p N(R d ) 2 ,
(9) —N(R d ) 2 ,
(10) —O(CR d R d ) n N(R d ) 2 ,
(11) —C(O)R d ,
(12) —CO 2 R d ,
(13) —CO 2 (CR d R d ) n CON(R d ) 2 ,
(14) —OC(O)R d ,
(15) —CN,
(16) —C(O)N(R d ) 2 ,
(17) —NR d C(O)R d ,
(18) —OC(O)N(R d ) 2 ,
(19) —NR d C(O)OR d ,
(20) —NR d C(O)N(R d ) 2 ,
(21) —CR d (N—OR d ),
(22) —CF 3 ,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;
each R b is independently selected from:
(1) R a ,
(2) —Sn(CH 3 ) 3 ,
(3) C 1-10 alkyl,
(4) C 2-10 alkenyl,
(5) C 2-10 alkynyl,
(6) heteroaryl,
(7) aryl, and
(8) aryl-C 1-10 alkyl;
wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl are optionally substituted with one to four substituents selected from a group independently selected from R c ;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) —CF 3 ,
(10) —OC(O)C 1-4 alkyl,
(11) —OC(O)N(R d ) 2 , and
(12) aryloxy;
R d is independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl; C 2-6 alkynyl; cycloalkyl; cycloalkyl-C 1-6 alkyl; cycloheteroalkyl; cycloheteroalkyl-C 1-6 alkyl; aryl; heteroaryl; aryl-C 1-6 alkyl; and heteroaryl-C 1-6 alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R d are optionally substituted with one to four substituents independently selected from R e ;
each R e is selected from halo, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;
m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, 4, and 5;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 , wherein:
R 1 and R 2 are independently selected from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) C 2-6 alkenyl,
(4) cycloalkyl-C 0-6 alkyl,
(5) heterocycloalkyl-C 0-6 alkyl,
(6) aryl-C 0-6 alkyl, and
(7) heteroaryl-C 0-10 alkyl;
wherein alkyl and alkenyl moieties above are optionally substituted with one to three substituents independently selected from R a ; wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R b ;
or, R 1 and R 2 together with the nitrogen atom to which they are attached, form a 4- to 11-membered bridged or unbridged or spirocyclic heterocyclic ring, optionally containing one additional heteroatom selected from N, S, and O, optionally having one or more degrees of unsaturation, optionally fused to a 6-membered heteroaromatic or aromatic ring, either unsubstituted or substituted with an R b substituent;
R 3 and R 4 are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C 1-8 alkyl,
(4) trifluoromethyl,
(5) C 2-6 alkenyl,
(6) cycloalkyl,
(7) cycloalkyl-C 1-6 alkyl,
(8) cycloheteroalkyl,
(9) cycloheteroalkyl-C 1-6 alkyl,
(10) aryl,
(11) aryl-C 1-6 alkyl,
(12) heteroaryl,
(13) heteroaryl-C 1-6 alkyl,
(14) —OR 7 ,
(15) —NR 7 R 7 ,
(16) —CO 2 R 7 , and
(17) —C(O)NR 7 R 7 ;
wherein alkyl and alkenyl moieties above are optionally substituted with one to four substituents independently selected from R a ; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R b substituent;
R 5 is
hydrogen
(10);
R 6 is selected from the group consisting of:
(1) —(CH 2 ) n -heteroaryl-R 7 ,
(2) —(CH 2 ) n NR 7 C(O)R 7 , and
(3) —(CH 2 ) n N(R 7 ) 2 ,
wherein one or two of the hydrogen atoms in (CH 2 ) n may be substituted with R a ;
R 7 is independently selected at each occurrence from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,
(6) heterocycloalkyl,
(7) aryl C 1-3 alkyl,
(8) heteroaryl C 1-3 alkyl,
(9) cycloalkyl C 1-3 alkyl,
(10) heterocycloalkyl C 1-3 alkyl,
(11) aryl C 2-3 alkenyl,
(12) heteroaryl C 2-3 alkenyl,
(13) cycloalkyl C 2-3 alkenyl, and
(14) heterocycloalkyl C 2-3 alkenyl,
wherein the alkyl and alkenyl moieties are optionally substituted with one to four substituents selected from R a ; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to four substituents selected from R b ; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
each R a is independently selected from:
(1) —OR d ,
(2) —NR d S(O) m R d ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m R d ,
(6) —SR d ,
(7) —S(O) 2 OR d ,
(8) —S(O) p N(R d ) 2 ,
(9) —N(R d ) 2 ,
(10) —O(CR d R d ) n N(R d ) 2 ,
(11) —C(O)R d ,
(12) —CO 2 R d ,
(13) —CO 2 (CR d R d ) n CON(R d ) 2 ,
(14) —OC(O)R d ,
(15) —CN,
(16) —C(O)N(R d ) 2 ,
(17) —NR d C(O)R d ,
(18) —OC(O)N(R d ) 2 ,
(19) —NR d C(O)OR d ,
(20) —NR d C(O)N(R d ) 2 ,
(21) —CR d (N—OR d ),
(22) —CF 3 ,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;
each R b is independently selected from:
(1) R a ,
(2) —Sn(CH 3 ) 3 ,
(3) C 1-10 alkyl,
(4) C 2-10 alkenyl,
(5) heteroaryl,
(6) aryl, and
(7) aryl-C 1-10 alkyl;
wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl are optionally substituted with one to four R c substituents;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) —CF 3 ,
(10) —OC(O)C 1-4 alkyl,
(11) —OC(O)N(R d ) 2 , and
(12) aryloxy;
each R d is independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl; C 2-6 alkynyl; cycloalkyl; cycloalkyl-C 1-6 alkyl; cycloheteroalkyl; cycloheteroalkyl-C 1-6 alkyl; aryl; heteroaryl; aryl-C 1-6 alkyl; and heteroaryl-C 1-6 alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R d are optionally substituted with one to two substituents independently selected from a R e ;
each R e is selected from halo, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;
m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, 4, and 5;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.
3. The compound according to claim 2 , wherein:
R 1 is selected from the group consisting of:
(1) hydrogen, and
(2) C 1-6 alkyl, optionally substituted with one to three substituents independently selected from R a ;
R 2 is selected from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) cycloalkyl-C 0-6 alkyl,
(4) heterocycloalkyl-C 0-6 alkyl,
(5) aryl-C 0-6 alkyl, and
(6) heteroaryl-C 0-10 alkyl;
wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R a ; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R b ;
or, R 1 and R 2 together with the nitrogen atom to which they are attached, form a 4- to 11-membered bridged or unbridged or spirocyclic heterocyclic ring, optionally containing one additional heteroatom selected from N, S, and O, either unsubstituted or substituted with an R b substituent;
R 3 is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C 1-8 alkyl,
(4) trifluoromethyl,
(5) —OH,
(6) —OCH 3 ,
(7) —NH 2 ,
(8) —CO 2 R 7 , and
(9) —C(O)NH 2 ;
wherein alkyl moieties above are optionally substituted with one to two substituents independently selected from R a ;
R 4 is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C 1-8 alkyl,
(4) trifluoromethyl,
(5) cycloalkyl,
(6) cycloheteroalkyl,
(7) aryl,
(8) aryl-C 1-6 alkyl,
(9) heteroaryl,
(10) —OH,
(11) —OCH,
(12) —NH 2 ,
(13) —CO 2 R 7 , and
(14) —C(O)NH 2 ;
wherein alkyl moieties above are optionally substituted with one to four substituents independently selected from R a ; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R b substituent;
R 5 is
hydrogen
(10);
R 6 is selected from the group consisting of:
(1) —(CH 2 ) n -heteroaryl-R 7 ,
(2) —(CH 2 ) n NR 7 C(O)R 7 , and
(3) —(CH 2 ) n N(R 7 ) 2 ,
wherein one or two of the hydrogen atoms in (CH 2 ) n may be substituted with R a ;
R 7 is independently selected at each occurrence from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,
(6) heterocycloalkyl,
(7) aryl C 1-3 alkyl,
(8) heteroaryl C 1-3 alkyl,
(9) cycloalkyl C 1-3 alkyl,
(10) heterocycloalkyl C 1-3 alkyl,
(11) aryl C 2-3 alkenyl,
(12) heteroaryl C 2-3 alkenyl,
(13) cycloalkyl C 2-3 alkenyl, and
(14) heterocycloalkyl C 2-3 alkenyl,
wherein the alkyl and alkenyl moieties are optionally substituted with one to three substituents selected from R a ; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to three substituents selected from R b ; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
each R a is independently selected from:
(1) —OR d ,
(2) —NR d S(O) m R d ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m R d ,
(6) —SR d ,
(7) —S(O) 2 OR d ,
(8) —S(O) p N(R d ) 2 ,
(9) —N(R d ) 2 ,
(10) —O(CR d R d ) n N(R d ) 2 ,
(11) —C(O)R d ,
(12) —CO 2 R d ,
(13) —CO 2 (CR d R d ) n CON(R d ) 2 ,
(14) —OC(O)R d ,
(15) —CN,
(16) —C(O)N(R d ) 2 ,
(17) —NR d C(O)R d ,
(18) —OC(O)N(R d ) 2 ,
(19) —NR d C(O)OR d ,
(20) —NR d C(O)N(R d ) 2 ,
(21) —CR d (N—OR d ),
(22) —CF 3 ,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;
each R b is independently selected from:
(1) R a ,
(2) —Sn(CH 3 ) 3 ,
(3) C 1-10 alkyl,
(4) C 2-10 alkenyl,
(5) heteroaryl,
(6) aryl, and
(7) aryl-C 1-10 alkyl;
wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl moieties in R a and R b are optionally substituted with one to four R c substituents;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) —CF 3 ,
(10) —OC(O)C 1-4 alkyl,
(11) —OC(O)N(R d ) 2 , and
(12) aryloxy;
R d is independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl; C 2-6 alkynyl; cycloalkyl; cycloalkyl-C 1-6 alkyl; cycloheteroalkyl; cycloheteroalkyl-C 1-6 alkyl; aryl; heteroaryl; aryl-C 1-6 alkyl; and heteroaryl-C 1-6 alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R d are optionally substituted with one to two substituents independently selected from a R e ;
each R e is selected from halo, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;
m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, and 4;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.
4. The compound according to claim 3 , wherein:
R 1 is selected from the group consisting of:
(1) hydrogen,
(2) methyl,
(3) ethyl, and
(4) propyl,
optionally substituted with one to three substituents independently selected from R a ;
R 2 is selected from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) cycloalkyl-C 0-6 alkyl,
(4) heterocycloalkyl-C 0-6 alkyl, and
(5) aryl-C 0-6 alkyl,
wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R a ; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R b ;
or, R 1 and R 2 together with the nitrogen atom to which they are attached, form a 4- to 11-membered bridged or unbridged or spirocyclic heterocyclic ring, optionally containing one additional heteroatom selected from N, S, and O, either unsubstituted or substituted with an R b substituent;
R 3 is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C 1-8 alkyl, and
(4) trifluoromethyl,
wherein alkyl moieties above are optionally substituted with one to two substituents independently selected from R a ;
R 4 is selected from the group consisting of:
(1) hydrogen,
(2) C 1-8 alkyl,
(3) trifluoromethyl,
(4) cycloalkyl,
(5) cycloheteroalkyl,
(6) aryl,
(7) heteroaryl,
(8) —NH 2 ,
(9) —CO 2 H,
(10) —CO 2 CH 3 , and
(11) —CO 2 CH 2 CH 3 ;
wherein alkyl moieties above are optionally substituted with one to two substituents independently selected from R a ; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R b substituent;
R 5 is
hydrogen
(6);
R 6 is selected from the group consisting of:
(1) —(CH 2 ) n -heteroaryl-R 7 ,
(2) —(CH 2 ) n NR 7 C(O)R 7 , and
(3) —(CH 2 ) n N(R 7 ) 2 ,
wherein one or two of the hydrogen atoms in (CH 2 ) n may be substituted with R a ;
R 7 is independently selected at each occurrence from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,
(6) heterocycloalkyl,
(7) aryl C 1-3 alkyl,
(8) heteroaryl C 1-3 alkyl,
(9) cycloalkyl C 1-3 alkyl,
(10) heterocycloalkyl C 1-3 alkyl,
(11) aryl C 2-3 alkenyl,
(12) heteroaryl C 2-3 alkenyl,
(13) cycloalkyl C 2-3 alkenyl, and
(14) heterocycloalkyl C 2-3 alkenyl,
wherein the alkyl and alkenyl moieties are optionally substituted with one to three substituents selected from R a ; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to three substituents selected from R b ; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
each R a is independently selected from:
(1) —OR d ,
(2) —NHSO 2 CH 3 ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m CH 3 ,
(6) —SR d ,
(7) —S(O) 2 OR d ,
(8) —S(O) p N(R d ) 2 ,
(9) —N(R d ) 2 ,
(10) —O(CR d R d ) n N(R d ) 2 ,
(11) —C(O)R d ,
(12) —CO 2 R d ,
(13) —CO 2 (CR d R d ) n CON(R d ) 2 ,
(14) —OC(O)R d ,
(15) —CN,
(16) —C(O)N(R d ) 2 ,
(17) —NR d C(O)R d ,
(18) —OC(O)N(R d ) 2 ,
(19) —NR d C(O)OR d ,
(20) —NR d C(O)N(R d ) 2 ,
(21) —CR d (N—OR d ),
(22) —CF 3 ,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;
each R b is independently selected from:
(1) R a ,
(2) —Sn(CH 3 ) 3 ,
(3) C 1-6 alkyl,
(4) C 2-6 alkenyl,
(5) heteroaryl,
(6) aryl, and
(7) aryl-C 1-10 alkyl;
wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl moieties in R a and R b are optionally substituted with one to four R c substituents;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) —CF 3 ,
(10) —OC(O)C 1-4 alkyl,
(11) —OC(O)N(R d ) 2 , and
(12) aryloxy;
R d is independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl; C 2-6 alkynyl; cycloalkyl; cycloalkyl-C 1-6 alkyl; cycloheteroalkyl; cycloheteroalkyl-C 1-6 alkyl; aryl; heteroaryl; aryl-C 1-6 alkyl; and heteroaryl-C 1-6 alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R d are optionally substituted with one to two substituents independently selected from a R e ;
each R e is selected from halogen, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;
m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, and 4;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.
5. The compound according to claim 4 , wherein:
R 1 is selected from the group consisting of:
(1) hydrogen, and
(2) methyl;
optionally substituted with one to three substituents independently selected from R a ;
R 2 is selected from the group consisting of:
(1) methyl,
(2) ethyl,
(3) n-propyl,
(4) isopropyl,
(5) t-butyl,
(6) n-butyl,
(7) cyclopropyl,
(8) cyclobutyl,
(9) cyclopentyl,
(10) cyclohexyl,
(11) heterocycloalkyl-C 0-6 alkyl, wherein the heterocycloalkyl moiety is selected from azetidinyl, pyrrolidinyl, and pyridyl and
(12) phenyl-C 0-6 alkyl,
wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R a ; and wherein cycloalkyl, heterocycloalkyl, and aryl moieties above are optionally substituted with one to three substituents independently selected from R b ;
or, R 1 and R 2 together with the nitrogen atom to which they are attached, form a 4- to 11-membered heterocyclic ring, selected from: azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, 1-thia-4-azacyclohexyl, 2,5-diazabicyclo[2.2.2]octanyl, azacycloheptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 7-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.2]octyl, and 3-azabicyclo[3.2.2]nonyl, 2,7-diazaspiro[4.4]nonyl, 2,7-diazaspiro[4.5]decyl, 2,7-diazaspiro[4.6]undecyl, 1,7-diazaspiro[4.4]nonyl, 2,6-dizaospiro[4.5]decyl, 2,6-diazaspiro[4.6]-undecyl, either unsubstituted or substituted with an R b substituent;
R 3 is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) methyl,
(4) ethyl,
(5) propyl, and
(6) trifluoromethyl,
wherein alkyl moieties above are optionally substituted with one to two substituents independently selected from R a ;
R 4 is selected from the group consisting of:
(1) hydrogen,
(2) methyl,
(3) ethyl,
(4) propyl,
(5) trifluoromethyl,
(6) —CO 2 H,
(7) —CO 2 CH 3 and
(8) —CO 2 CH 2 CH 3 ;
wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R a ;
R 5 is hydrogen;
R 6 is selected from the group consisting of:
(1)-heteroaryl-R 7 ,
(2) —NHC(O)R 7 ,
(3) —NH(R 7 ), and
(4) —(CH 2 ) n NH(R 7 ),
wherein one or two of the hydrogen atoms in (CH 2 ) n may be substituted with R a ;
R 7 is independently selected at each occurrence from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) aryl, selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,
(4) heteroaryl, selected from: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,
(5) cycloalkyl, selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo[2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl,
(6) heterocycloalkyl, selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl, indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl,
(7) aryl C 1-3 alkyl, wherein the aryl moiety is selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,
(8) heteroaryl C 1-3 alkyl, wherein the heteroaryl moiety is selected: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,
(9) cycloalkyl C 1-3 alkyl, wherein the cycloalkyl moiety is selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo[2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl,
(10) heterocycloalkyl C 1-3 alkyl, wherein the heterocycloalkyl moiety is selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl, indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl,
(11) aryl C 2-3 alkenyl, wherein the aryl moiety is selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,
(12) heteroaryl C 2-3 alkenyl, wherein the heteroaryl moiety is selected from: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,
(13) cycloalkyl C 2-3 alkenyl, wherein the cycloalkyl moiety is selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo[2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl, and
(14) heterocycloalkyl C 2-3 alkenyl, wherein the heterocycloalkyl moiety is selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl, indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl;
wherein the alkyl moieties are optionally substituted with one to three substituents selected from R a ; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to three substituents selected from R b ; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
each R a is independently selected from:
(1) —OR d ,
(2) —NHSO 2 CH 3 ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m CH 3 ,
(6) —SCH 3 ,
(7) —SCF 3 ,
(8) —S(O) 2 OR d ,
(9) —S(O) p N(R d ) 2 ,
(10) —N(CH 3 ) 2 ,
(11) —NH 2 ,
(12) —O(CR d R d ) n N(R d ) 2 ,
(13) —C(O)R d ,
(14) —CO 2 H,
(15) —CO 2 CH 3 ,
(16) t-butyloxycarbonyl,
(17) —CO 2 (CR d R d ) n CON(R d ) 2 ,
(18) —OC(O)R d ,
(19) —CN,
(20) —C(O)N(R d ) 2 ,
(21) —NR d C(O)R d ,
(22) —OC(O)N(R d ) 2 ,
(23) —NR d C(O)OR d ,
(24) —NR d C(O)N(R d ) 2 ,
(25) —CR d (N—OR d ),
(26) —CF 3 ,
(27) cycloalkyl,
(28) cycloheteroalkyl, and
(29) oxo;
each R b is independently selected from:
(1) —R a ,
(2) —Sn(CH 3 ) 3 ,
(3) C 1-6 alkyl,
(4) C 2-6 alkenyl,
(5) heteroaryl,
(6) aryl, and
(7) aryl-C 1-10 alkyl;
wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl moieties in R a and R b are optionally substituted with one to four R c substituents;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) —CF 3 ,
(10) —OC(O)C 1-4 alkyl,
(11) —OC(O)N(R d ) 2 , and
(12) aryloxy;
R d is independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl; C 2-6 alkynyl; cycloalkyl; cycloalkyl-C 1-6 alkyl; cycloheteroalkyl; cycloheteroalkyl-C 1-6 alkyl; aryl; heteroaryl; aryl-C 1-6 alkyl; and heteroaryl-C 1-6 alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R d are optionally substituted with one to two substituents independently selected from a R e ;
each R e is selected from halogen, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;
m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, and 4;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.
6. The compound according to claim 1 of structural formula:
wherein: R 7 and R are as illustrated in the table below:
Ex. #
R 7
R = NR 1 R 2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1 of structural formula:
wherein: R 7 and R are as illustrated in the table below:
Ex. #
R 7
R = NR 1 R 2
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1 of structural formula:
wherein: R 7 , R 4 and R are as illustrated in the table below:
Ex. #
R 7
R 4
R = NR 1 R 2
311
—CH 3
312
—CH 3
313
—CH 3
314
—CH 3
315
—CH 2 CH 3
316
—CH 2 CH 3
317
—CH 2 CH 3
318
—CH 2 CH 3
319
—CO 2 CH 3
320
—CO 2 CH 3
or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 1 , selected from:
(1) (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide,
(2) (2E)-N-[2-(dimethylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(3) (2E)-3-(4-chlorophenyl)-N-[2-(ethylamino)quinolin-6-yl]prop-2-enamide,
(4) (2E)-N-[2-(ethylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(5) (2E)-3-(4-chlorophenyl)-N-[2-(propylamino)quinolin-6-yl]prop-2-enamide,
(6) (2E)-N-[2-(propylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(7) (2E)-3-(4-chlorophenyl)-N-[2-(isopropylamino)quinolin-6-yl]prop-2-enamide,
(8) (2E)-N-[2-(isopropylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(9) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-(4-chlorophenyl)prop-2-enamide,
(10) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(11) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)-3-methylquinolin-6-yl]-3-(4-chlorophenyl)prop-2-enamide,
(12) (2E)-N-[2-(dimethylamino)-4-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(13) N-[2-(dimethylamino)-4-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(14) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]—N′-[4-(methylthio)phenyl]urea,
(15) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[6-(trifluoromethyl)pyridin-3-yl]propanamide,
(16) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-[4-(trifluoromethoxy)phenyl]urea,
(17) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-(4-ethylphenyl)prop-2-enamide,
(18) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(4-isopropylphenyl)urea,
(19) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-(4-ethylphenyl)propanamide,
(20) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-[4-(trifluoromethyl)phenyl]urea,
(21) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(4-methoxyphenyl)urea,
(22) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-(4-methoxyphenyl)prop-2-enamide,
(23) N-[2-(dimethylamino)quinolin-6-yl]-N′-[4-(methylthio)phenyl]urea,
(24) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)-4-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(25) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)-4-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(26) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(4-ethylphenyl)urea,
(27) N-(2-pyrrolidin-1-ylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(28) (2E)-N-(2-pyrrolidin-1-ylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(29) (2E)-N-(2-azetidin-1-ylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(30) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(31) N-(2-azetidin-1-ylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(32) (2E)-N-[2-(butylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(33) (2E)-N-[2-(isobutylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(34) N-[2-(isobutylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(35) (2E)-N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(36) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(2,3-dihydro-1H-inden-5-yl)urea,
(37) (2E)-N-[2-(sec-butylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(38) N-[2-(sec-butylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(39) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(4-propylphenyl)urea,
(40) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(41) N-[2-(cyclopentylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(42) N-(2-{[(1R)-1-methylpropyl]amino}quinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(43) (2E)-N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(44) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide
(45) N-(2-{[(1S)-1-methylpropyl]amino}quinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(46) N-(3-methyl-2-pyrrolidin-1-ylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(47) (2E)-N-(4-ethyl-2-pyrrolidin-1-ylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(48) N-[2-(3-methylpyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(49) N-[2-(2-methylpyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(50) N-{2-[(1,2-dimethylpropyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(51) N-{2-[ethyl(methyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(52) N-{2-[methyl(propyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(53) N-(2-azetidin-1-yl-3-methylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(54) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(2,2-difluoro-1,3-benzodioxol-5-yl)urea,
(55) N-[2-(isopropylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(56) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-3-[6-(trifluoromethyl)pyridin-3-yl]propanamide,
(57) N-(2-azetidin-1-yl-3-methylquinolin-6-yl)-N′-[4-(trifluoromethyl)phenyl]urea,
(58) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-N′-[4-(trifluoromethyl)phenyl]urea,
(59) N-(3-methyl-2-pyrrolidin-1-ylquinolin-6-yl)-N′-[4-(trifluoromethyl)phenyl]urea,
(60) N-{2-[(1-methylbutyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(61) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-(2,2-difluoro-1,3-benzodioxol-5-yl)urea,
(62) N-[2-(2-azabicyclo[2.2.2]hept-2-yl)quinolin-6-yl]-N′-(2-methyl-1,3-benzothiazol-6-yl)urea,
(63) N-{2-[cyclopentyl(methyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(64) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-N′-[4-(trifluoromethyl)phenyl]propanamide,
(65) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-{4-[(trifluoromethyl)thio]phenyl}urea,
(66) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-3-[6-(trifluoromethyl)pyridin-3-yl]propanamide,
(67) N-{2-[cyclobutyl(methyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(68) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-(1,3-benzothiazol-2-yl)propanamide,
(69) N-{2-[(1R,4S)-2-azabicyclo[2.2.1]hept-2-yl]quinolin-6-yl}-3-[6-(trifluoromethyl)pyridin-3-yl]propanamide,
(70) N-{2-[(1S,4R)-2-azabicyclo[2.2.1]hept-2-yl]quinolin-6-yl}-3-[6yl]propanamide,
(71) (2E)-N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(72) (2E)-3-(4-chlorophenyl)-N-{2-[isopropyl(methyl)amino]quinolin-yl}prop-2-enamide,
(73) N-[2-(pyrrolidin-3-ylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(74) N-{2-[3-(acetylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(75) N-[2-(3-{[(methylamino)carbonyl]amino}pyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(76) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-(4-ethylphenyl)urea,
(77) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[4-(methylthio)phenyl]prop-2-enamide,
(78) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-{4-[(trifluoromethyl)thio]phenyl}urea,
(79) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-[4-(methylthio)phenyl]urea,
(80) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-[4-(trifluoromethoxy)phenyl]urea,
(81) N-{2-[methyl(tetrahydrofuran-3-yl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(82) N-(2-{3-[(methylsulfonyl)amino]pyrrolidin-1-yl}quinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(83) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-3-(1,3-benzothiazol-2-yl)propanamide,
(84) N-{2-[sec-butyl(methyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(85) N-{2-[3-(propionylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(86) 2-{methyl[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]amino}propylacetate,
(87) N-{2-[methyl(1-tetrahydrofuran-2-ylethyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(88) N-[2-(3-{[(dimethylamino)carbonyl]amino}pyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(89) 2-methyl-N-{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(90) N-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(91) N-{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}cyclohexanecarboxamide,
(92) N-(4-ethylphenyl)-N′-{2-[isopropyl(methyl)amino]quinolin-6-yl}urea,
(93) 2,2-dimethyl-N-{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(94) (2E)-N-[2-(3-aminopyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide
(95) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-N′-[4-(methylthio)phenyl]urea,
(96) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-N′-[4-(trifluoromethyl)phenyl]urea,
(97) N-{1-[6-({[(4-ethylphenyl)amino]carbonyl}amino)quinolin-2-yl]pyrrolidin-3-yl}-2,2-dimethylpropanamide,
(98) N-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}-N′-(4-ethylphenyl)urea,
(99) tert-butyl methyl{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}carbamate,
(100) N-(2,2-difluoro-1,3-benzodioxol-5-yl)-N′-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}urea,
(101) N-{2-[(3S)-3-aminopyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(102) N-{2-[3-(methylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(103) 2,2-dimethyl-N-{(3S)-1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(104) 2,2-dimethyl-N-{(3R)-1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(105) N,2,2-trimethyl-N-{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(106) N-{2-[(3S)-3-(propionylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(107) (2E)-N-(2-{3-[(methylsulfonyl)amino]pyrrolidin-1-yl}quinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(108) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[4-(ethylthio)phenyl]prop-2-enamide,
(109) tert-butyl 1-(6-{[(2E)-3-(4-chlorophenyl)prop-2-enoyl]amino}quinolin-2-yl)pyrrolidin-3-ylcarbamate,
(110) (2E)-N-[2-(3-aminopyrrolidin-1-yl)quinolin-6-yl]-3-(4-chlorophenyl)prop-2-enamide,
(111) N-{1-[6-({[(4-ethylphenyl)amino]carbonyl}amino)quinolin-2-yl]pyrrolidin-3-yl}methanesulfonamide,
(112) N-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}-N′-[4-(trifluoromethyl)phenyl]urea,
(113) N-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}-N′-[4-(trifluoromethoxy)phenyl]urea,
(114) N-{2-[(3R)-3-(propionylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(115) N-[2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide, (116) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N 2 -(4-ethylphenyl)ethane-1,2-diamine,
(117) N-[2-(7-benzyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(118) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-4-(dimethylamino)quinolin-6-yl]-4′-(trifluoromethyl)-1,1′-biphenyl-4-carboxamide,
(119) N-[2-(2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(120) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-N′-[4-(trifluoromethoxy)phenyl]urea,
(121) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-[6-(trifluoromethyl)pyridin-3-yl]urea,
(122) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-(6-ethylpyridin-3-yl)urea,
(123) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[4-(methylsulfonyl)phenyl]propanamide,
(124) 2,2-dimethyl-N-{1-[6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(125) 1-[6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-2-yl]pyrrolidin-3-amine,
(126) N-{1-[6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(127) 2-methyl-N-{1-[6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(128) N-{1-[6-(3-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-5-yl)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
and pharmaceutically accepted salts thereof.
10. The compound according to claim 9 , selected from:
(1) (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide,
(2) (2E)-N-[2-(dimethylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(3) (2E)-N-[2-(ethylamino)quinolin-6-yl]-3-[4-(trifluoromethlyl)phenyl]prop-2-enamide,
(4) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-(4-chlorophenyl)prop-2-enamide,
(5) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(6) (2E)-N-[2-(dimethylamino)-4-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(7) N-[2-(dimethylamino)4-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(8) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-[4-(methylthio)phenyl]urea,
(9) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[6-(trifluoromethyl)pyridin-3-yl]propanamide,
(10) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-[4-(trifluoromethoxy)phenyl]urea,
(11) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(4-isopropylphenyl)urea,
(12) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-(4-ethylphenyl)propanamide,
(13) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-[4-(trifluoromethyl)phenyl]urea,
(14) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(4-methoxyphenyl)urea,
(15) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-(4-methoxyphenyl)prop-2-enamide,
(16) N-[2-(dimethylamino)quinolin-6-yl]-N′-[4-(methylthio)phenyl]urea,
(17) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(4-ethylphenyl)urea,
(18) N-(2-pyrrolidin-1-ylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(19) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(20) N-(2-azetidin-1-ylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(21) N-[2-(isobutylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(22) (2E)-N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(23) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(2,3-dihydro-1H-inden-5-yl)urea,
(24) N-[2-(sec-butylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(25) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(4-propylphenyl)urea,
(26) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(27) N-[2-(cyclopentylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(28) N-(2-{[(1R)-1-methylpropyl]amino}quinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(29) (2E)-N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(30) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(31) N-[2-(3-methylpyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(32) N-[2-(2-methylpyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(33) N-(2-azetidin-1-yl-3-methylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(34) N-[2-(isopropylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(35) N-{2-[isopropyl(methyl)amino]quinolin-6-yl }-3-[6-(trifluoromethyl)pyridin-3-yl]propanamide,
(36) N-(2-azetidin-1-yl-3-methylquinolin-6-yl)-N′-[4-(trifluoromethyl)phenyl]urea,
(37) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-N′-[4-(trifluoromethmethyl)phenyl]urea,
(38) N-(3-methyl-2-pyrrolidin-1-ylquinolin-6-yl)-N′-[4-(trifluoromethyl)phenyl]urea,
(39) N-{2-[cyclopentyl(methyl)amino]quinolin-6-yl )-3-[4-(trifluoromethyl)phenyl]propanamide,
(40) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-N′-[4-(trifluoromethoxy)phenyl]urea,
(41) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-{4-[(trifluoromethyl)thio]phenyl}urea,
(42) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)-3-methylquinolin-6-yl]-3-[6-(trifluoromethylpyridin-3-yl]propanamide,
(43) N-{2-[(1R,4S)-2-azabicyclo[2.2.1]hept-2-yl]quinolin-6-yl}-3-[6-(trifluoromethyl)pyridin-3-yl]propanamide,
(44) N-{2-[(1S,4R)-2-azabicyclo[2.2.1]hept-2-yl]quinolin-6-yl}-3-[6-trifluoromethyl)pyridin-3-yl]propanamide,
(45) (2E)-N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(46) (2E)-3-(4-chlorophenyl)-N-{2-[isopropyl(methyl)amino]quinolin-6-yl}prop-2-enamide
(47) N-[2-(pyrrolidin-3-ylamino)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(48) N-{2-[3-(acetylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(49) N-[2-(3-{[(methylamino)carbonyl]amino}pyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(50) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-(4-ethylphenyl)urea,
(51) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[4-(methylthio)phenyl]prop-2-enamide,
(52) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-{4-[(trifluoromethyl)thio]phenyl}urea,
(53) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-[4-(methylthio)phenyl]urea,
(54) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-N′-[4-(trifluoromethoxy)phenyl]urea,
(55) N-{2-[methyl(tetrahydrofuran-3-yl)amino]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(56) N-(2-{3-[(methylsulfonyl)amino]pyrrolidin-1-yl}quinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(57) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)quinolin-6-yl]-3-(1,3-benzothiazol-2-yl)propanamide,
(58) N-{2-[3-(propionylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(59) N-[2-(3-{[(dimethylamino)carbonyl]amino}pyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(60) 2-methyl-N-{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(61) N-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(62) N-{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}cyclohexanecarboxamide,
(63) 2,2-dimethyl-N-{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(64) (2E)-N-[2-(3-aminopyrrolidin-1-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(65) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-N′-[4-(methylthio)phenyl]urea,
(66) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-N′-[4-(trifluoromethyl)phenyl]urea,
(67) N-{1-[6-({[(4-ethylphenyl)amino]carbonyl}amino)quinolin-2-yl]pyrrolidin-3-}-2,2-dimethylpropanamide,
(68) N-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}-N′-(4-ethylphenyl)urea,
(69) N-{2-[(3S)-3-aminopyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(70) N-{2-[3-(methylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethylphenyl]propanamide,
(71) 2,2-dimethyl-N-{(3S)-1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(72) 2,2-dimethyl-N-{(3R)-1-[6-(3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(73) N,2,2-trimethyl-N-{1-[6-({3-[4-(trifluoromethyl)phenyl]propanoyl}amino)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(74) N-{2-[(3S)-3-(propionylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(75) (2E)-N-(2-{3-[(methylsulfonyl)amino]pyrrolidin-1-yl}quinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(76) (2E)-N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[4-(ethylthio)phenyl]prop-2-enamide,
(77) tert-butyl 1-(6-{[(2E)-3-(4-chlorophenyl)prop-2-enoyl]amino}quinolin-2-yl)pyrrolidin-3-ylcarbamate,
(78) (2E)-N-[2-(3-aminopyrrolidin-1-yl)quinolin-6-yl]-3-(4-chlorophenyl)prop-2-enamide,
(79) N-{1-[6-({[(4-ethylphenyl)amino]carbonyl}amino)quinolin-2-yl]pyrrolidin-3-yl}methanesulfonamide,
(80) N-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}-N′-[4-(trifluoromethyl)phenyl]urea,
(81) N-{2-[3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl}-N′-[4-(trifluoromethoxy)phenyl]urea,
(82) N-{2-[(3R)-3-(propionylamino)pyrrolidin-1-yl]quinolin-6-yl}-3-[4-(trifluoromethyl)phenyl]propanamide,
(83) N-[2-(7-methyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(84) N′-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N 2 -(4-ethylphenyl)ethane-1,2-diamine,
(85) N-[2-(7-benzyl-2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(86) N-[2-(2-azabicyclo[2.2.1]hept-2-yl)4-(dimethylamino)quinolin-6-yl]-4′-trifluoromethyl)-1,1′-biphenyl-4-carboxamide,
(87) N-[2-(2,7-diazaspiro[4.4]non-2-yl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(88) N-{2-[isopropyl(methyl)amino]quinolin-6-yl}-N′-[4-(trifluoromethoxy)phenyl]urea,
(89) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-[6-(trifluoromethyl)pyridin-3-yl]urea,
(90) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-N′-(6-ethylpyridin-3-yl)urea,
(91) N-[2-(2-azabicyclo[2.2.2]oct-2-yl)quinolin-6-yl]-3-[4-(methylsulfonyl)phenyl]propanamide,
(92) 2,2-dimethyl-N-{1-[6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(93) 1-[6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-2-yl]pyrrolidin-3-amine,
(94) N-{1-[6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(95) 2-methyl-N-{1-[6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
(96) N-{1-[6-(3-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-5-yl)quinolin-2-yl]pyrrolidin-3-yl}propanamide,
and pharmaceutically acceptable salts thereof.
11. A method of treating or suppressing a disease mediated by the MCH receptor by reducing food intake in a subject in need thereof comprising administration of a therapeutically effective amount of a compound according to claim 1 .
12. The method according to claim 11 wherein the disease is mediated by the MCH 1 R receptor.
13. A method of treating obesity in a subject in need thereof comprising administration of a therapeutically effective amount of a compound according to claim 1 .
14. The method according to claim 13 , additionally comprising administration of a therapeutically effective amount of an anorectic agent or a selective serotonin reuptake inhibitor.
15. The method according to claim 14 wherein the anorectic agent is selected from: aminorex, amphechloral, amphetamine, benzphetamine, chlorphentermine, clobenzorex, cloforex, clominorex, clortermine, cyclexedrine, dexfenfluramine, dextroamphetamine, diethylpropion, diphemethoxidine, N-ethylamphetamine, fenbutrazate, fenfluramine, fenisorex, fenproporex, fludorex, fluminorex, furfurylmethylamphetamine, levamfetamine, levophacetoperane, mazindol, mefenorex, metamfepramone, methamphetamine, norpseudoephedrine, pentorex, phendimetrazine, phenmetrazine, phentermine, phenylpropanolamine, picilorex and sibutramine; and the selective serotonin reuptake inhibitor is selected from: fluoxetine, fluvoxamine, paroxetine and sertraline.
16. A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.01 mg to about 100 mg per kg of a compound according to claim 1 .
17. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
18. A method of treating depression in a subject in need thereof comprising administering an effective amount of an MCH-1R receptor antagonist compound according to claim 1 to the subject.